12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tivantinib: Phase III discontinued

ArQule and Asian partner Kyowa discontinued the double-blind, Asian Phase III ATTENTION trial of tivantinib based on a recommendation by the trial's safety committee. ATTENTION was comparing tivantinib plus Tarceva erlotinib vs. Tarceva alone in 460 EGFR wild-type patients with locally advanced or metastatic, non-squamous NSCLC who received 1-2 prior systemic cancer therapies. In August, the partners suspended enrollment in the trial following an imbalance of interstitial lung disease between treatment arms. ArQule said data from ATTENTION are expected...

Read the full 392 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >